 | • レポートコード：MRC2301H158 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、223ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料では、2021年に370.7億ドルであった世界の女性用健康診断市場規模が、2022年に403.4億ドルになり、2027年まで年平均9.00%で成長して621.8億ドルに拡大すると予測しています。本資料は、女性用健康診断の世界市場について調べ、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（ポイントオブケア、セルフチェック）分析、用途別（乳がん検査、子宮頸がん検査、感染症検査、骨粗鬆症検査、その他）分析、エンドユーザー別（画像診断センター、在宅医療、病院・診療所）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、Abbott Laboratories、AccuBioTech Co., Ltd.、Alere Inc.、Becton, Dickinson and Company、Biomérieux SA、Cardinal Health, Inc.、Carestream Health, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の女性用健康診断市場規模：種類別 - ポイントオブケアにおける市場規模 - セルフチェックにおける市場規模 ・世界の女性用健康診断市場規模：用途別 - 乳がん検査における市場規模 - 子宮頸がん検査における市場規模 - 感染症検査における市場規模 - 骨粗鬆症検査における市場規模 - その他における市場規模 ・世界の女性用健康診断市場規模：エンドユーザー別 - 画像診断センターにおける市場規模 - 在宅医療における市場規模 - 病院・診療所における市場規模 ・世界の女性用健康診断市場規模：地域別 - 南北アメリカの女性用健康診断市場規模 アメリカの女性用健康診断市場規模 カナダの女性用健康診断市場規模 ブラジルの女性用健康診断市場規模 … - アジア太平洋の女性用健康診断市場規模 日本の女性用健康診断市場規模 中国の女性用健康診断市場規模 インドの女性用健康診断市場規模 韓国の女性用健康診断市場規模 台湾の女性用健康診断市場規模 … - ヨーロッパ/中東/アフリカの女性用健康診断市場規模 イギリスの女性用健康診断市場規模 ドイツの女性用健康診断市場規模 フランスの女性用健康診断市場規模 ロシアの女性用健康診断市場規模 … - その他地域の女性用健康診断市場規模 ・競争状況 ・企業情報 |
The Global Women’s Health Diagnostics Market size was estimated at USD 37.07 billion in 2021 and expected to reach USD 40.34 billion in 2022, and is projected to grow at a CAGR 9.00% to reach USD 62.18 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Women’s Health Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Point-of-care and Self Check.
Based on Application, the market was studied across Breast Cancer Testing, Cervical Cancer Testing, Infectious Disease Testing, Osteoporosis Testing, Ovarian Cancer Testing, Pregnancy and Fertility Testing, Prenatal Genetic Screening and Carrier Testing, Sexually Transmitted Disease Testing, and Ultrasound Tests. The Breast Cancer Testing is further studied across Biopsies, Blood Chemistries and Blood Cell Count Tests, Breast Cancer Tumor Marker Tests, and Mammography. The Cervical Cancer Testing is further studied across HPV Testing and PAP Smear. The Infectious Disease Testing is further studied across HEPAtitis Testing, MRSA Testing, Tuberculosis Testing, and Urinary Tract Infection Testing (Vaginal Ph & Vaginitis). The Osteoporosis Testing is further studied across Bone Densitometry and in Vitro Blood Tests. The Ovarian Cancer Testing is further studied across Diagnostic Imaging Tests and Ovarian Cancer Tumor Marker Tests. The Pregnancy and Fertility Testing is further studied across Fertility Monitors, Lab-Based Testing, and Pregnancy Testing and Ovulation Prediction Kits. The Prenatal Genetic Screening and Carrier Testing is further studied across Cystic Fibrosis, Down Syndrome and Edwards Syndrome, and Torch Infections. The Sexually Transmitted Disease Testing is further studied across Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing and HIV Testing. The Ultrasound Tests is further studied across Breast Imaging and OB/GYN Imaging.
Based on End User, the market was studied across Diagnostic and Imaging Centers, Home Care, and Hospitals and Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Women’s Health Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Women’s Health Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Women’s Health Diagnostics Market, including Abbott Laboratories, AccuBioTech Co., Ltd., Alere Inc., Becton, Dickinson and Company, Biomérieux SA, Cardinal Health, Inc., Carestream Health, Inc., Chembio Diagnostic Systems, Inc., Cook Medical, Inc., Danaher Corporation, DIALAB GmbH, EKF Diagnostics Holdings plc, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, GE Healthcare, Guided Therapeutics, Inc., Hologic, Inc., Koninklijke Philips N.V., MedGyn Products, Inc., NeuroLogica Corporation, Nova Biomedical, Osteometer MediTech, Inc., Perkinelmer Inc., Quest Diagnostics Incorporated, Siemens AG, SuperSonic Imagine, and WerfenLife, S.A..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Women’s Health Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Women’s Health Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Women’s Health Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Women’s Health Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Women’s Health Diagnostics Market?
6. What is the market share of the leading vendors in the Global Women’s Health Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Women’s Health Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing instances of chronic and life style- related disorders in women
5.1.1.2. Awareness about fertility testing in women coupled with initiatives taken by health organizations and government
5.1.1.3. Adoption of point-of-care and rapid diagnostic tests
5.1.1.4. Availability of imaging and private diagnostic centres
5.1.1.5. PPP to develop the modern infrastructure of diagnostic imaging centres
5.1.2. Restraints
5.1.2.1. Limited technically skilled lab assistants
5.1.3. Opportunities
5.1.3.1. Improved and technically advanced healthcare infrastructure in emerging economies
5.1.3.2. Regulatory approvals for immunoassay diagnostics techniques
5.1.3.3. Growing focus on microfluidics and nanotechnology-based POC devices for diagnostic
5.1.3.4. Clinical trial assessment for the diagnosis of breast cancer
5.1.4. Challenges
5.1.4.1. High cost associated with procedures and diagnostic imaging systems
5.1.4.2. Stringent regulatory guidelines
5.2. Cumulative Impact of COVID-19
6. Women’s Health Diagnostics Market, by Type
6.1. Introduction
6.2. Point-of-care
6.3. Self Check
7. Women’s Health Diagnostics Market, by Application
7.1. Introduction
7.2. Breast Cancer Testing
7.3.1. Biopsies
7.3.2. Blood Chemistries and Blood Cell Count Tests
7.3.3. Breast Cancer Tumor Marker Tests
7.3.4. Mammography
7.3. Cervical Cancer Testing
7.4.1. HPV Testing
7.4.2. PAP Smear
7.4. Infectious Disease Testing
7.5.1. HEPAtitis Testing
7.5.2. MRSA Testing
7.5.3. Tuberculosis Testing
7.5.4. Urinary Tract Infection Testing (Vaginal Ph & Vaginitis)
7.5. Osteoporosis Testing
7.6.1. Bone Densitometry
7.6.2. in Vitro Blood Tests
7.6. Ovarian Cancer Testing
7.7.1. Diagnostic Imaging Tests
7.7.2. Ovarian Cancer Tumor Marker Tests
7.7. Pregnancy and Fertility Testing
7.8.1. Fertility Monitors
7.8.2. Lab-Based Testing
7.8.3. Pregnancy Testing and Ovulation Prediction Kits
7.8. Prenatal Genetic Screening and Carrier Testing
7.9.1. Cystic Fibrosis
7.9.2. Down Syndrome and Edwards Syndrome
7.9.3. Torch Infections
7.9. Sexually Transmitted Disease Testing
7.10.1. Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing
7.10.2. HIV Testing
7.10. Ultrasound Tests
7.11.1. Breast Imaging
7.11.2. OB/GYN Imaging
8. Women’s Health Diagnostics Market, by End User
8.1. Introduction
8.2. Diagnostic and Imaging Centers
8.3. Home Care
8.4. Hospitals and Clinics
9. Americas Women’s Health Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Women’s Health Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Women’s Health Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AccuBioTech Co., Ltd.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Alere Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Becton, Dickinson and Company
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Biomérieux SA
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Cardinal Health, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Carestream Health, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Chembio Diagnostic Systems, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Cook Medical, Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Danaher Corporation
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. DIALAB GmbH
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. EKF Diagnostics Holdings plc
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. F. Hoffmann-La Roche Ltd.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. FUJIFILM Holdings Corporation
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. GE Healthcare
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Guided Therapeutics, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Hologic, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Koninklijke Philips N.V.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. MedGyn Products, Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. NeuroLogica Corporation
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Nova Biomedical
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Osteometer MediTech, Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Perkinelmer Inc.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Quest Diagnostics Incorporated
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Siemens AG
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. SuperSonic Imagine
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. WerfenLife, S.A.
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing